Sanofi $SNY Stock Holdings Trimmed by Dorsey & Whitney Trust CO LLC

Dorsey & Whitney Trust CO LLC decreased its holdings in Sanofi (NASDAQ:SNY) by 20.4% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 19,473 shares of the company’s stock after selling 4,998 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Sanofi were worth $941,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Ameritas Advisory Services LLC bought a new position in Sanofi in the 2nd quarter valued at about $28,000. Accent Capital Management LLC acquired a new stake in shares of Sanofi in the 1st quarter worth approximately $29,000. Eastern Bank lifted its stake in shares of Sanofi by 121.0% in the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock worth $30,000 after acquiring an additional 300 shares during the period. Banque Transatlantique SA bought a new position in shares of Sanofi in the first quarter valued at approximately $33,000. Finally, Brentview Investment Management LLC acquired a new position in shares of Sanofi during the first quarter valued at approximately $42,000. 14.03% of the stock is currently owned by institutional investors.

Sanofi Trading Down 2.2%

Shares of NASDAQ SNY opened at $50.66 on Wednesday. The company has a quick ratio of 0.94, a current ratio of 1.06 and a debt-to-equity ratio of 0.16. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12. The company has a market cap of $124.40 billion, a price-to-earnings ratio of 11.86, a P/E/G ratio of 1.38 and a beta of 0.49. The business has a fifty day simple moving average of $49.16 and a 200-day simple moving average of $49.35.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 24th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.10. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The firm had revenue of $14.53 billion for the quarter, compared to the consensus estimate of $12.62 billion. During the same quarter in the previous year, the company earned $2.25 EPS. The business’s revenue for the quarter was down 7.5% compared to the same quarter last year. Sell-side analysts predict that Sanofi will post 4.36 EPS for the current year.

Wall Street Analysts Forecast Growth

SNY has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $56.00 to $58.00 in a research note on Monday, September 8th. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a research report on Monday, October 27th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a research report on Tuesday, November 11th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $62.67.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.